NCT03367624Unknown不适用
Epidemiology of Post-influenza Bacterial Pneumonia Due to a Panton-Valentine Leukocidin Positive Staphylococcus Aureus
Central Hospital, Nancy, France1 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2017年10月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- Number of dead patients
研究概览
简要总结
Secondary bacterial influenza pneumonia caused by Panton-Valentine Leukocidin Positive Staphylococcus aureus is a rare complication but with poor prognosis. This pathology seems to affect young patients (20-40 years) without any medical history. Since the influenza pandemic of 2009, this complication is more and more mentioned, sought and diagnosed. However, the literature is poor, consisting of case reports, experimental studies on murine models, and low-power studies.
The main objective is to evaluate the mortality in intensive care units of patients post-influenza bacterial pneumonia due to a Panton-Valentine Leukocidin positive Staphylococcus aureus
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient treated for post-influenza bacterial pneumonia due to a Panton-Valentine Leukocidin positive Staphylococcus aureus in intensive care unit
排除标准
- •Minor patient
- •Patient under protective measurement
- •Absence of bacteriological and / or virological documentation
结局指标
主要结局
Number of dead patients
时间窗: During Length of stay in intensive care unit (an average of 2 weeks)
All cause of mortality
次要结局
- Demographic data relating to age(Baseline)
- Demographic data relating to sex(Baseline)
- Respiratory failure(Baseline)
- Demographic data relating to immunosuppression(Baseline)
- risk factors for methicillin-resistant Staphylococcus aureus(Baseline)
- Clinical data relating to pre-admission antibiotics(Baseline)
- Clinical data in the initial phase relating to SAPS 2 score(Baseline)
- Clinical data in the initial phase relating to SOFA admission(Baseline)
- Clinical data in the initial phase relating to neutropenia(During Length of stay in intensive care unit (an average of 2 weeks))
- Clinical data in the initial phase relating to metabolic acidosis(During Length of stay in intensive care unit (an average of 2 weeks))
- Clinical data in the initial phase relating to oxygen dependence(During Length of stay in intensive care unit (an average of 2 weeks))
- Clinical data in the initial phase relating to hyperthermia(During Length of stay in intensive care unit (an average of 2 weeks))
- Clinical data in the initial phase relating to chills(During Length of stay in intensive care unit (an average of 2 weeks))
- Clinical data in the initial phase relating to headhache(During Length of stay in intensive care unit (an average of 2 weeks))
- Clinical data in the initial phase relating to acute respiratory failure(During Length of stay in intensive care unit (an average of 2 weeks))
- Clinical data in the initial phase relating to hemoptysis(During Length of stay in intensive care unit (an average of 2 weeks))
- Clinical data in the initial phase relating to productive cough(During Length of stay in intensive care unit (an average of 2 weeks))
- Clinical data in the initial phase relating to dyspnoea(During Length of stay in intensive care unit (an average of 2 weeks))
- Clinical data in the initial phase relating to uni - or multi - lobar infiltration on chest X - ray or CT scan(During Length of stay in intensive care unit (an average of 2 weeks))
- Clinical data in the initial phase relating to pleural effusion(During Length of stay in intensive care unit (an average of 2 weeks))
- Clinical data in the initial phase(During Length of stay in intensive care unit (an average of 2 weeks))
- Clinical data in the initial phase relating to renal failure(During Length of stay in intensive care unit (an average of 2 weeks))
- Collection of infectious samples(During Length of stay in intensive care unit (an average of 2 weeks))
- Prognostic factors for this pathology(During Length of stay in intensive care unit (an average of 2 weeks))
- Complications(During Length of stay in intensive care unit (an average of 2 weeks))
- Dosage of antiviral treatment(During Length of stay in intensive care unit (an average of 2 weeks))
- Number of patients with Influenza type B(During Length of stay in intensive care unit (an average of 2 weeks))
- Date of initiation of anti-viral treatment in relation to the onset of symptoms and duration of anti-viral treatment(During Length of stay in intensive care unit (an average of 2 weeks))
- Probabilistic antibiotherapy(During Length of stay in intensive care unit (an average of 2 weeks))
- Prescribed antibiotic therapy(During Length of stay in intensive care unit (an average of 2 weeks))
- Collection of the date of introduction of adapted antibiotic therapy(During Length of stay in intensive care unit (an average of 2 weeks))
- Number of patients with Influenza type A(During Length of stay in intensive care unit (an average of 2 weeks))
- Number of serious influenza infections per year and per center with early and late deaths(During Length of stay in intensive care unit (an average of 2 weeks))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Increasing the Uptake of Influenza and Pneumococcal Vaccines Among High-Risk Adult Patients Through GP ClinicsImmunization ProgramsNCT03445117Tan Tock Seng Hospital8,837
进行中（未招募）
不适用
Pathogens Involved in Secondary Infections During Severe Forms of Covid-19 Pneumonia:Covid19Ventilator Associated PneumoniaNosocomial PneumoniaNCT04488510Fondation Hôpital Saint-Joseph22
已完成
不适用
Prospective Observational Trial of IAPAInfluenza With PneumoniaPulmonary AspergillosisNCT04530799Radboud University Medical Center241
已完成
不适用
The Predictive Value of Clinical and Immunological Factors in the Development of Pneumonia After Traumatic Brain InjuryTraumatic Brain InjuryNCT00929448Royal Alexandra Hospital110
招募中
不适用
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.Pneumonia, Community-AcquiredCOVID-19 PneumoniaCardiovascular DiseasesNCT06601998Hellenic Institute for the Study of Sepsis650